According to a whistleblower complaint, in September 2018, Michael Mullen of National Securities Corporation (NSC) allegedly engaged in insider trading of stocks of TG Therapeutics—a subsidiary of NSC’s parent company Fortress Biotech, Inc—days before the biopharmaceutical company announced the disappointing results of their clinical trials for “U2,” a potential treatment for chronic lymphocytic leukemia. According…

Read More

A class action lawsuit has been filed against TG Therapeutics, Inc. and certain of the company’s officers in connection to alleged failures to disclose material facts regarding securities sold between September 15, 2014 and October 12, 2016. Fitapelli Kurta is interested in speaking to investors who have complaints regarding TG Therapeutics (NASDAQ: TGTX). The complaint…

Read More